Overview

Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2024-02-29

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in the body (metastatic). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may work better in treating patients with colorectal cancer compared to standard treatments.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Array BioPharma
Bristol-Myers Squibb
Bristol-Myers Squibb (BMS)
Pfizer

Treatments:

Nivolumab